» Articles » PMID: 36409730

New Multimodal Intervention to Reduce Irritable Bowel Syndrome (IBS) Severity Symptoms-Pilot Study with a 12 Month Follow-up

Overview
Journal PLoS One
Date 2022 Nov 21
PMID 36409730
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Irritable bowel syndrome (IBS) is characterized by patients' high level of suffering. Up to 60% of patients with IBS have symptoms of anxiety or depression and only little attention has been paid to their specific requirements. Anthroposophical multimodal therapy (AMT) has been shown to significantly improve health-related quality of life of patients with high symptomatic burden.

Objective: The aim of this pilot study was to find out whether AMT meets the needs of IBS patients and the interactions of AMT with IBS, depression and anxiety.

Methods: Patients with diagnosed IBS were included in a feasibility study and received 12 sessions of AMT over 8 weeks (drks.de, DRKS00016890). The primary endpoint was the change of the IBS severity score (IBS-SSS) and changes were calculated by linear mixed effects analyses. The secondary endpoints were changes of self-reported PHQ-9 and GAD-7 for mental comorbidity as well as self-valued effectiveness and satisfaction of AMT.

Results: Thirty-six patients, 89% female, were included in the study. AMT was successfully applied to IBS patients (-45 points in the IBS-SSS, p < .05). AMT had a large positive effect (-84 points in IBS-SSS, p < .003) on patients without anxiety or depression. Over time, patients with higher anxiety scores worsened with regard to their IBS compared to patients with depression and without mental comorbidity. The AMT effect was maintained at a 12 month follow up and both mentally affected and unaffected patients, had even lower IBS severity than shortly after AMT. AMT modules were rated by IBS patients as very effective.

Conclusion: Our findings suggest that an 8-week program of AMT improves the severity of IBS with an ongoing effect at a 12 month follow-up. Especially for patients without psychological comorbidities, AMT is very successful. Future IBS therapies should incorporate a modified multimodal concept with stronger psychological therapy modules in parallel for patients with depression and anxiety.

Citing Articles

The Value of PHQ-9 and GAD-7 for Screening Emotional Disorders in IBS-D and the Specificity of the Gut Flora Associated with Emotional Comorbidity: Preliminary Findings.

Zhao J, Li X, Wang X, Wang X, Hao X, Li Z Neuropsychiatr Dis Treat. 2024; 20:2145-2158.

PMID: 39564595 PMC: 11573876. DOI: 10.2147/NDT.S486784.


New multimodal intervention to reduce irritable bowel syndrome (IBS) severity symptoms-Pilot study with a 12 month follow-up.

Hinse M, Thronicke A, Berghofer A, Matthes H PLoS One. 2022; 17(11):e0277880.

PMID: 36409730 PMC: 9678296. DOI: 10.1371/journal.pone.0277880.

References
1.
Spitzer R, Kroenke K, Williams J, Lowe B . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166(10):1092-7. DOI: 10.1001/archinte.166.10.1092. View

2.
Abbing A, Baars E, de Sonneville L, Ponstein A, Swaab H . The Effectiveness of Art Therapy for Anxiety in Adult Women: A Randomized Controlled Trial. Front Psychol. 2019; 10:1203. PMC: 6549595. DOI: 10.3389/fpsyg.2019.01203. View

3.
Huber M, Knottnerus J, Green L, van der Horst H, Jadad A, Kromhout D . How should we define health?. BMJ. 2011; 343:d4163. DOI: 10.1136/bmj.d4163. View

4.
Field A, Wilcox R . Robust statistical methods: A primer for clinical psychology and experimental psychopathology researchers. Behav Res Ther. 2017; 98:19-38. DOI: 10.1016/j.brat.2017.05.013. View

5.
Bercik P, Collins S, Verdu E . Microbes and the gut-brain axis. Neurogastroenterol Motil. 2012; 24(5):405-13. DOI: 10.1111/j.1365-2982.2012.01906.x. View